Find your therapeutic targets and make more informed decisions with our patient-derived xenograft (PDX) tumor sources. PDX models preserve the heterogeneity of tumors, providing the best representation of the original patient tumors for in vivo efficacy studies.
To empower your PDX modeling, Inotiv offers the highly characterized and well-regarded Washington University Human In Mouse (WHIM) Breast Cancer PDX Model Collection and the Wistar Melanoma (WM) PDX Model Collection.
Given that only 13% of cancer compounds make it to market and the average cost to reach the clinic is close to $1B, emphasizing the need for robust preclinical research. PDX models help bridge the translational gap between preclinical research and the clinic by improving clinical predictability in a highly complex environment.
Learn more about our PDX solutions for your research
Bring clarity to your research faster with our collection of well-characterized patient-derived xenografts.